细胞和基因治疗临床试验服务市场- 按服务（临床试验设计和规划）、阶段、适应症、治疗类型（基因、细胞、基因修饰细胞疗法）、最终用途（製药和生物技术、CRO） - 全球预测（ 2024 - 2032)

由于 CRISPR-Cas9 和病毒载体等技术升级以及支持性监管环境，全球细胞和基因疗法临床试验服务市场规模从 2024 年到 2032 年将以 10.8 的复合年增长率扩大。这些创新增强了治疗潜力并简化了审批流程，刺激了更多的研究和试验活动。随着 FDA 等监管机构加快突破性疗法的批准，生物技术公司和製药公司投资和加速新型疗法开发的势头不断增强，从而推动了市场成长。

例如，2023 年 6 月，FDA 成立了一个新办公室，负责处理激增的细胞和基因疗法申请，包括可能批准第一种 CRISPR 疗法和杜氏肌肉营养不良症基因疗法。这一发展标誌着监管活动和行业动力的加强，刺激了支持这些试验的服务提供者的成长机会，从患者招募到监管合规性和资料管理。

细胞放大器基因疗法临床试验服务产业根据服务、阶段、适应症、治疗类型、最终用途和地区而分散。

由于对神经系统疾病有效治疗的迫切需求，神经病学领域到 2032 年将取得显着进展。随着帕金森氏症、阿兹海默症和肌萎缩侧索硬化症等疾病的研究不断深入，针对这些领域的治疗方法投入了大量资金。神经病学临床试验受益于专业知识、强大的患者招募网络和监管支持，使其成为创新的焦点。基因编辑和细胞疗法的进步为解决未满足的医疗需求提供了一个有希望的途径，进一步增强了这一领域的突出地位。

由于学术和研究机构在开拓创新疗法和进行早期试验方面发挥关键作用，到 2032 年，学术和研究机构领域将大幅成长。这些机构拥有广泛的专业知识、基础设施和接触对推进研究至关重要的患者群体的机会。与生物技术公司的合作和政府资助增强了他们的能力。随着对尖端疗法的需求不断增长，学术和研究机构将进行必要的临床试验，以验证细胞和基因疗法的安全性和有效性。

由于医疗基础设施投资增加、遗传性疾病盛行率上升以及支持性监管环境，亚太地区细胞放大器基因治疗临床试验服务市场份额在 2024 年至 2032 年间将出现显着的复合年增长率。该地区多样化的患者群体和较低的营运成本吸引了全球生物技术和製药公司进行临床试验。随着中国、日本和韩国等国家在生物技术和基因研究方面的进步，亚太地区将成为全球细胞放大器基因疗法临床试验服务产业扩张的关键贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病和遗传疾病的发生率上升
    • 细胞和基因治疗的技术进步
    • 增加研发活动投资
    • 扩大在肿瘤学和罕见疾病领域的应用
  • 产业陷阱与挑战
    • 严格的监管挑战
    • 开发成本高
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按服务分类，2021-2032 年

• 主要趋势
• 临床试验设计与规划
• 供应及物流服务
• 监管事务与合规
• 数据管理和生物统计学
• 现场管理和监控
• 其他服务

第 6 章：市场估计与预测：按阶段，2021-2032 年

• 主要趋势
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第 7 章：市场估计与预测：按指标划分，2021-2032 年

• 主要趋势
• 肿瘤学
• 血液学
• 内分泌/代谢紊乱
• 传染病
• 神经病学
• 心血管疾病
• 肌肉骨骼疾病
• 其他适应症

第 8 章：市场估计与预测：按治疗类型，2021-2032 年

• 主要趋势
• 基因治疗
• 细胞疗法
• 基因修饰细胞疗法

第 9 章：市场估计与预测：依最终用途，2021-2032 年

• 主要趋势
• 製药和生物技术公司
• 合约研究组织
• 学术及研究机构
• 其他最终用户

第 10 章：市场估计与预测：按地区划分，2021-2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• ADVARRA
• Charles River Laboratories International Inc.
• Catalent Pharma
• ICON PLC
• IQVIA
• Medpace, Inc.
• Novotech
• Precision Medicine Group, LLC
• Parexel International
• Syneos Health
• Sharp Services, LLC
• Thermo Fisher Scientific Inc.
• Worldwide Clinical Trials

Global Cell & Gene Therapy Clinical Trial Services Market size will expand at a 10.8 CAGR from 2024 to 2032, attributed to technological upgrades, such as CRISPR-Cas9 and viral vectors, in line with supportive regulatory environments. These innovations enhance therapeutic potential and streamline approval processes, stimulating increased research and trial activities. With regulatory agencies like the FDA facilitating faster approvals for groundbreaking therapies, there is a growing momentum among biotech firms and pharmaceutical companies to invest in and accelerate the development of novel treatments, fueling market growth.

For instance, in June 2023, the FDA launched a new office to handle a surge in cell and gene therapy submissions, including potential approvals for the first CRISPR therapy and gene therapy for Duchenne muscular dystrophy. This development signifies heightened regulatory activity and industry momentum, stimulating growth opportunities for service providers supporting these trials, ranging from patient recruitment to regulatory compliance and data management.

The cell & gene therapy clinical trial services industry is fragmented based on service, phase, indication, therapy type, end-use, and region.

The neurology segment will garner remarkable gains through 2032, spurred by the pressing need for effective treatments for neurological disorders. With conditions like Parkinson's, Alzheimer's, and ALS driving research, there is a substantial investment in therapies targeting these areas. Clinical trials in neurology benefit from specialized expertise, robust patient recruitment networks, and regulatory support, making it a focal point for innovation. Advances in gene editing and cell therapies offer promising avenues for addressing unmet medical needs, further bolstering this segment's prominence.

The academic and research institutions segment will see a considerable surge by 2032, owing to their pivotal role in pioneering innovative therapies and conducting early-stage trials. These institutions possess extensive expertise, infrastructure, and access to patient populations critical for advancing research. Collaborations with biotech firms and government funding bolster their capabilities. As demand grows for cutting-edge therapies, academic and research institutions will conduct essential clinical trials that validate the safety and efficacy of cell and gene therapies.

Asia Pacific cell & gene therapy clinical trial services market share will experience a notable CAGR between 2024 and 2032 due to increasing investments in healthcare infrastructure, rising prevalence of genetic disorders, and supportive regulatory environments. The region's diverse patient population and lower operational costs attract global biotech and pharmaceutical firms to conduct clinical trials. As countries like China, Japan, and South Korea advance in biotechnology and genetic research, Asia Pacific will stand as a key contributor to the expansion of the global cell & gene therapy clinical trial services industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and genetic disease
    • 3.2.1.2 Technological advancement in cell and gene therapy
    • 3.2.1.3 Increasing investment in research & development activities
    • 3.2.1.4 Expanded application in oncology and rare disease
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory challenges
    • 3.2.2.2 High development cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Service, 2021-2032 ($ Million)

• 5.1 Key trends
• 5.2 Clinical trial design & planning
• 5.3 Supply & logistics services
• 5.4 Regulatory affairs & compliance
• 5.5 Data management & biostatistics
• 5.6 Site management & monitoring
• 5.7 Other services

Chapter 6 Market Estimates and Forecast, By Phase, 2021-2032 ($ Million)

• 6.1 Key trends
• 6.2 Phase I
• 6.3 Phase II
• 6.4 Phase III
• 6.5 Phase IV

Chapter 7 Market Estimates and Forecast, By Indication, 2021-2032 ($ Million)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Hematology
• 7.4 Endocrine/metabolic disorders
• 7.5 Infectious diseases
• 7.6 Neurology
• 7.7 Cardiovascular diseases
• 7.8 Musculoskeletal disorders
• 7.9 Other indications

Chapter 8 Market Estimates and Forecast, By Therapy Type, 2021-2032 ($ Million)

• 8.1 Key trends
• 8.2 Gene therapy
• 8.3 Cell therapy
• 8.4 Gene modified cell therapy

Chapter 9 Market Estimates and Forecast, By End-Use, 2021-2032 ($ Million)

• 9.1 Key trends
• 9.2 Pharmaceutical & biotechnology companies
• 9.3 Contract research organizations
• 9.4 Academic & research institutes
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021-2032 ($ Million)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 ADVARRA
• 11.2 Charles River Laboratories International Inc.
• 11.3 Catalent Pharma
• 11.4 ICON PLC
• 11.5 IQVIA
• 11.6 Medpace, Inc.
• 11.7 Novotech
• 11.8 Precision Medicine Group, LLC
• 11.9 Parexel International
• 11.10 Syneos Health
• 11.11 Sharp Services, LLC
• 11.12 Thermo Fisher Scientific Inc.
• 11.13 Worldwide Clinical Trials